ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer.
Koca E, Niravath PA, Ensor J, Patel TA, Li X, Hemati P, Wong H, Qian W, Boone T, Zhao J, Ramshesh PV, Cohen AL, Murthy A, Nair S, Darcourt JG, Belcheva A, Kaklamani VG, Chang JCN.
Koca E, et al. Among authors: li x.
Breast Cancer Res Treat. 2021 Jul;188(2):433-439. doi: 10.1007/s10549-021-06214-7. Epub 2021 Apr 15.
Breast Cancer Res Treat. 2021.
PMID: 33860388
Clinical Trial.